Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Corcept Therapeutics Inc (NASDAQ:CORT)

16.61
Delayed Data
As of Dec 15
 0.00 / 0.00%
Today’s Change
6.70
Today|||52-Week Range
20.77
+128.79%
Year-to-Date
Shire's New Formulation of Oncaspar Gets Approval in Europe
Dec 14 / Zacks.com - Paid Partner Content
Lilly Reports Mixed Results from Late-Stage Cyramza Study
Dec 11 / Zacks.com - Paid Partner Content
Regeneron, Sanofi Report Positive Top Line Skin Cancer Data
Dec 13 / Zacks.com - Paid Partner Content
Roche Reports Tecentriq/Avastin Lung Cancer Study Data
Dec 07 / Zacks.com - Paid Partner Content
Allergan Inks Deal to Buy Texas-Based Repros Therapeutics
Dec 13 / Zacks.com - Paid Partner Content
Revance's Neuromodulator Injection Positive in Phase III
Dec 06 / Zacks.com - Paid Partner Content
Proteostasis Stock Surges on Positive Data From CF Studies
Dec 13 / Zacks.com - Paid Partner Content
Here's Why Sarepta Stock is Up More Than 70% in 6 Months
Dec 05 / Zacks.com - Paid Partner Content
Glaxo's Nucala Label Expansion Application Gets FDA Approval
Dec 13 / Zacks.com - Paid Partner Content
AstraZeneca's COPD Drug Succeeds in Label Expansion Study
Dec 05 / Zacks.com - Paid Partner Content
Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
Dec 12 / Zacks.com - Paid Partner Content
Ironwood Succeeds in Diabetic Hypertension Phase II Study
Dec 05 / Zacks.com - Paid Partner Content
Spark Therapeutics Stock Plunges on Hemophilia Therapy Data
Dec 12 / Zacks.com - Paid Partner Content
Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug
Dec 04 / Zacks.com - Paid Partner Content